Enterprise

Forty Seven

Public Company

With a passion to help patients defeat their cancer, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

fortyseveninc.com

Services/Other

U.S.

Leaders
Mark McCamish, M.D., Ph.D.

President & CEO

Chris Takimoto, M.D., Ph.D.

Chief Medical Officer

Craig Gibbs, Ph.D., M.B.A.

Chief Business Officer

Lightspeed Team

With a passion to help patients defeat their cancer, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.